https://www.globenewswire.com/news-release/2022/12/15/2575164/0/en/Cerevel-Therapeutics-Announces-Publication-in-The-Lancet-of-Emraclidine-Data-from-Phase-1b-Clinical-Trial-in-People-Living-with-Schizophrenia.html
0
0
12/15/22 at 11:30pm
Organization
GlobeNewswire
Author
Cerevel Therapeutics
42 words
0
Comments
Emraclidine is being developed as a potential once-daily treatment for schizophrenia without the need for titration Data show clinically meaningful...
You are the first to view
Create an account
or login to join the discussion